Ampio Pharma: Rises on expansion of COVID-19 drug study to India

Ampio Pharmaceuticals

15/06/2021 11:48

** Drug developer's shares  AMPE.A  rise ~34% to $2.41
premarket
    ** Co says U.S. FDA has granted approval to expand
enrollment of its mid-stage study, testing inhaled version of
lead drug candidate, Ampion, in treatment of COVID-19 patients,
to India (https://refini.tv/3cHGGUt)
    ** Co says it is discontinuing the study in Israel due to
political unrest in region and reduction in COVID-19 cases, and
will focus its resources to India and other regions outside U.S.
depending on magnitude of cases
    ** AMPE expects expansion to shorten the timeline for
overall study enrollment
    ** Stock up ~13% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))